Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome
Current Obesity Reports · 2025
DOI: 10.1007/s13679-025-00614-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Obesity Reports, 2025. Verfasst von Michail Diakosavvas und 2 weiteren Autor:innen. Beteiligte Einrichtung: Homerton Fertility Centre, Homerton Healthcare NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Obesity, Weight Reduction Programs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose of Review Polycystic Ovary Syndrome (PCOS) affects 10–15% of women of reproductive age and is associated with a heightened risk of metabolic morbidity, exacerbated by insulin resistance and obesity. Current weight management strategies have limited effectiveness in reducing metabolic morbidity in this subgroup. This review examines the potential of Intensive Weight Management Programmes (IWMPs) and Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to reduce metabolic risks in women with PCOS, drawing from studies in both PCOS-specific and related populations. Recent Findings IWMPs, including total diet replacement, achieve substantial and sustained weight loss (5–15% over 1–5 years) in individuals with obesity and type 2 diabetes, alongside improvements in metabolic markers like blood pressure and glycemic control. GLP-1 RAs, particularly semaglutide, similarly deliver significant weight loss (10–15% over 1–2 years) and metabolic benefits. While there is limited data specifically targeting PCOS, emerging studies suggest GLP-1 RAs can improve weight, insulin sensitivity, and menstrual regularity in this group. However, evidence for both interventions in PCOS remains insufficient. Summary Women with PCOS face unique metabolic challenges, including heightened insulin resistance, compounded by obesity. While IWMPs and GLP-1 RAs are promising interventions, evidence for their effectiveness in PCOS-specific populations is insufficient. Addressing this research gap through targeted trials is essential to improve outcomes in individuals affected by PCOS and metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Homerton Fertility Centre, Homerton Healthcare NHS Foundation Trust, London, UK.
- Centre for Public Health and Policy, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
- Homerton Fertility Centre, Homerton Healthcare NHS Foundation Trust, London, UK. p.bhide@qmul.ac.uk.
- Centre for Public Health and Policy, Wolfson Institute of Population Health, Queen Mary University of London, London, UK. p.bhide@qmul.ac.uk.
- , Yvonne Carter Building, 58 Turner Street, London, E12AB, UK. p.bhide@qmul.ac.uk.
ORCID-Profile: Michail Diakosavvas, Oyinlola Oyebode, Priya Bhide
Zitieren
APA
Diakosavvas, M., Oyebode, O., & Bhide, P. (2025). Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome. Current Obesity Reports. https://doi.org/10.1007/s13679-025-00614-2
Vancouver
Diakosavvas M, Oyebode O, Bhide P. Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome. Current Obesity Reports. 2025. doi:10.1007/s13679-025-00614-2
BibTeX
@article{Diakosavvas2025,
author = {Diakosavvas, Michail and Oyebode, Oyinlola and Bhide, Priya},
title = {Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome},
journal = {Current Obesity Reports},
year = {2025},
doi = {10.1007/s13679-025-00614-2}
}
EUVIMED